BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 424 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 424 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $25.46, for a total value of $10,795.04. Following the transaction, the chief marketing officer now owns 106,538 shares of the company’s stock, valued at $2,712,457.48. The trade was a 0.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Todd Berard also recently made the following trade(s):

• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS opened at $26.25 on Thursday. The stock’s 50-day moving average is $26.67 and its 200 day moving average is $25.48. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same period last year, the company earned ($0.21) EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on BLFS. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Benchmark reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. TD Cowen raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently bought and sold shares of BLFS. Harbor Capital Advisors Inc. grew its position in BioLife Solutions by 31.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 52,449 shares of the medical equipment provider’s stock worth $1,313,000 after acquiring an additional 12,421 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of BioLife Solutions by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after buying an additional 8,580 shares during the last quarter. Summit Global Investments bought a new stake in shares of BioLife Solutions in the 3rd quarter worth approximately $228,000. Curi RMB Capital LLC grew its position in shares of BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after buying an additional 2,283 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter worth approximately $57,000. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.